Miach Orthopaedics

Miach Orthopaedics is a commercial-stage medical device company pioneering a paradigm shift in ACL treatment with its BEAR (Bridge-Enhanced ACL Repair) Implant. Unlike traditional ACL reconstruction (ACLR), which replaces the torn ligament with a graft, the BEAR Implant is a bioresorbable scaffold that, when combined with a small amount of the patient's blood, creates an environment to facilitate the native ACL's healing. Supported by Level 1 clinical evidence, the implant received FDA approval in 2020 and is now available across the United States, offering potential benefits such as preserved native anatomy, better hamstring strength recovery, and a reduced trend in contralateral tears. The company is actively conducting post-market studies to build its long-term evidence base.

Bridge-enhanced healing platform utilizing a bioresorbable bovine collagen implant scaffold combined with the patient's own blood to create a protected environment for native tissue regeneration.

Miach's primary competition is the entrenched standard of care: autograft and allograft ACL reconstruction, supported by large orthopedic device companies (e.g., Stryker, Smith & Nephew, Johnson & Johnson). It also faces emerging competition from other companies developing ACL repair techniques and bio-enhanced scaffolds. Miach's first-mover FDA approval and Level 1 clinical evidence provide a significant, but not unassailable, competitive advantage.